RecruitingPhase 3NCT07062198
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease
Studying Early-onset autosomal dominant Alzheimer disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ScandiBio Therapeutics AB
- Principal Investigator
- Sevki SAHIN, Prof. Dr.Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, University of Health Sciences Istanbul 34766, Turkiye
- Intervention
- Combined metabolic activators(drug)
- Enrollment
- 845 target
- Eligibility
- 50 years · All sexes
- Timeline
- 2025 – 2026
Study locations (8)
- Department of Neurology and Neuroscience, Faculty of Medicine, Alaaddin Keykubat University, Alanya, Turkey (Türkiye)
- Ataturk University, Faculty of Medicine, Department of Neurology, Erzurum, Turkey; Movement Disorders and Neuromodulation Center, Ataturk University, Erzurum, Turkey (Türkiye)
- Behavioural Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey (Türkiye)
- Haydarpaşa Numune Training and Research Hospital, University of Health Sciences Istanbul, Istanbul, Turkey (Türkiye)
- Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, University of Health Sciences Istanbul, Istanbul, Turkey (Türkiye)
- SB Haseki Training and Research Hospital, Istanbul, University of Health Sciences Istanbul, Istanbul, Turkey (Türkiye)
- Sultan Abdülhamid Han Training and Research Hospital, University of Health Sciences Istanbul, Istanbul, Turkey (Türkiye)
- Umraniye Training and Research Hospital, University of Health Sciences Istanbul, Istanbul, Turkey (Türkiye)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07062198 on ClinicalTrials.govOther trials for Early-onset autosomal dominant Alzheimer disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07294885Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's DiseaseGeneral Hospital of Shenyang Military Region
- ENROLLING BY INVITATIONNCT07314190Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental DisorderFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- ENROLLING BY INVITATIONNANCT07425106Comparative Study of High Performance Low-Cost Optical Coherence Tomography (Stage 1B, 2 and 3)Duke University
- RECRUITINGPHASE2NCT07252440A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's DiseaseShanghai Auzone Biological Technology Co., Ltd.
- RECRUITINGPHASE3NCT06937229A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Bristol-Myers Squibb
- RECRUITINGNANCT07117162Improving Access to Care for Veterans With Memory LossVA Pittsburgh Healthcare System
- RECRUITINGNANCT07031687Effects and Mechanisms of Temporal Interference Brain Stimulation on Memory Function in Preclinical Alzheimer's DiseaseXuanwu Hospital, Beijing
- RECRUITINGPHASE2NCT07228078Open-Label Extension Protocol to SNK01-AD01 StudyNKGen Biotech, Inc.
See all trials for Early-onset autosomal dominant Alzheimer disease →